Daniel G. Kirby
Chief Commercial OfficerMr. Daniel G. Kirby, also known as Dan, is Chief Commercial Officer of Iovance Biotherapeutics, Inc. from February 10, 2025. He served as Chief Commercial Officer at Omeros Corporation until 2021, having held the position of vice president and head of commercial since December 3, 2018. He joined Omeros from Celgene, where he was the U.S. commercial lead for its chimeric antigen receptor (CAR) T-cell franchise. Before Celgene's acquisition of Juno Therapeutics, Mr. Kirby built and led the commercial marketing and market access functions as vice president and head of marketing/market access at Juno. Prior to his role at Juno, he was the head of marketing at Medivation, overseeing all marketing efforts for the blockbuster drug Xtandi®. Mr. Kirby has extensive experience in marketing and sales leadership roles, having spent many years at Amgen, where he advanced through various commercial positions of increasing responsibility. Before joining Amgen, he held commercial roles at GlaxoSmithKline. Before joining Iovance, Mr. Kirby led global commercial strategy for an emerging cell therapy platform of products as Chief Commercial Officer of Orca Bio. From 2018 to 2020, he served as Chief Commercial Officer at Omeros Corporation, where he oversaw U.S. and EU launch readiness for narsoplimab, a lectin pathway inhibitor, aimed at treating hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Earlier in his career, Mr. Kirby was Vice President and Head of US Cell and Gene at Celgene (now Bristol-Myers Squibb), where he led market access, reimbursement and marketing efforts for CAR T products. He also served as Head of Marketing for Medivation (now Pfizer) and held various commercial roles during a 14-year tenure at Amgen. Mr. Kirby's strengths include market engagement, reimbursement landscape evaluation, value story creation, key opinion leader outreach, communications and advocacy. His extensive background in commercial strategy and leadership positions him as a significant contributor to the biotechnology and pharmaceutical industries. He holds a B.A. from the University of Maryland.
Positions
- Company NameIovance Biotherapeutics, Inc.Stock CodeIOVAPositionChief Commercial OfficerColleagues
- FGFrederick G. VogtInterim CEO, President, General Counsel, Corporate Secretary & Director
- IDIain D. DukesIndependent Chairman of the Board
- CMCorleen M. RocheChief Financial Officer
- IPIgor P. BilinskyChief Operating Officer
- RKRaj K. PuriChief Regulatory Officer
- RDRyan D. MaynardIndependent Director
- MWMichael WeiserIndependent Director
- CYCassian YeeMember of Scientific Advisory Board
